4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Purity >98.5% (HPLC) Lenvatinib Mesylate Intermediate Factory
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates Ka Bohloeki bo Phahameng
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Lebitso la Lik'hemik'hale | 4-Chloro-7-Methoxyquinoline-6-Carboxamide |
Litlhaloso tse tšoanang | 4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Tšilafalo ea Lenvatinib 12;Tšilafalo ea Lenvatinib B;Tšilafalo ea Lenvatinib LFS-B |
Nomoro ea CAS | 417721-36-9 |
Nomoro ea KAtse | RF-PI1971 |
Boemo ba Setoko | Ka Setokong, Matla a Tlhahiso 50MT / Selemo |
Foromo ea limolek'hule | C11H9ClN2O2 |
Boima ba Molek'hule | 236.65 |
Melting Point | >205℃ (Dec.) |
Botenya | 1.380±0.060 g/cm3 |
Brand | Ruifu Chemical |
Ntho | Litlhaloso |
Ponahalo | Phofo e Bosoeu ho ea ho Bosehla bo Khanyang |
Mokhoa oa Bohloeki / Analysis | >98.5% (HPLC) |
Tahlehelo ka ho Omisa | <0.50% |
Masalla a ho Ignition | <0.50% |
Litšila ka Kakaretso | <1.50% |
Proton NMR Spectrum | E Ikamahanya le Sebopeho |
Tekanyetso ea Teko | Maemo a Khoebo |
Tšebeliso | Bohareng ba Lenvatinib Mesylate (CAS: 857890-39-2) |
Sephutheloana: Botlolo, Aluminium foil bag, 25kg/Cardboard Drum, kapa ho ea ka tlhokahalo ea moreki.
Boemo ba polokelo:Boloka ka lijaneng tse koetsoeng sebakeng se phodileng le se omileng;Sireletsa leseli le mongobo
4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) e sebelisoa haholo-holo e le bohareng ba Lenvatinib Mesylate (CAS: 857890-39-2).E thehiloe ke Eisai Inc., lenvatinib mesylate ke vascular endothelial growth factor receptor (VEGF) inhibitor e nang le ts'ebetso khahlano le VEGF subtypes 1, 2, le 3 mme e amohetsoe ke FDA ka 2015 bakeng sa kalafo ea mofets'e oa qoqotho o fapaneng o teng sebakeng sa heno. khafetsa, metastatic, kapa tsoelo-pele 'me ha ea ka ea arabela kalafo ea radioactive iodine.Ka Mots'eanong 2016, FDA e ile ea amohela sethethefatsi sena e le kalafo e kopaneng le everolimus bakeng sa kalafo ea advanced renal cell carcinoma.Hobane VEGF (le fibroblast growth factor receptors, e tsejoang e le FGFRs) ho nahanoa hore e phetha karolo ea litsela tsa matšoao a pelo, VEGF2R le FGFR inhibition ho nahanoa hore ke mekhoa e ka morao ea phello e ka sehloohong ea lenvatinib mesylate, e leng khatello ea mali.